James M. Lawrence
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Interests
James M. Lawrence has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Alan Young
Department of Diabetes and Endocrinology, Royal United Hospital, Bath BA1 3NG, bBatheaston Medical Centre, Batheaston, Bath BA1 7NP
1 shared publicationAnthony M Robinson
Department of Diabetes and Endocrinology, Royal United Hospital, Bath BA1 3NG, bBatheaston Medical Centre, Batheaston, Bath BA1 7NP
1 shared publicationAnthony Robinson
1 shared publicationC Stirling
Diabetes and Lipid Research, Wolfson Centre, Royal United Hospital, Wolfson Centre Combe Park, Bath BA1 3NG, UK
1 shared publicationChris Stirling
Diabetes and Lipid Research Group, Wolfson Centre, Royal United Hospital, Bath, U.K.
1 shared publicationG.J Taylor
Department of Medical Sciences, University of Bath, Bath, UK
1 shared publication
Latest Publications
- 31 May 2004
- Published by Elsevier in Atherosclerosis
- Vol. 174 (1) , 141-149
The effect of high dose atorvastatin therapy on lipids and lipoprotein subfractions in overweight patients with type 2 diabetes
- 31 May 2004
- Published by Elsevier in Atherosclerosis
- Vol. 174 (1) , 141-149
The effect of high dose atorvastatin therapy on lipids and lipoprotein subfractions in overweight patients with type 2 diabetes
- 1 January 2004
- Published by American Diabetes Association in Diabetes Care
- Vol. 27 (1) , 41-46
Favorable Effects of Pioglitazone and Metformin Compared With Gliclazide on Lipoprotein Subfractions in Overweight Patients With Early Type 2 Diabetes
OBJECTIVE—To compare effects of different oral hypoglycemic drugs as first-line therapy on lipoprotein subfractions in type 2 diabetes. RESEARCH DESIGN AND METHODS—Sixty overweight type 2 diabetic patients not on lipid-lowering therapy were randomized to metformin, pioglitazone, or gliclazide after a 3-month dietary run-in. Drug doses were uptitrated for 3 months to optimize glycemia and were kept fixed for a further 3 months. LDL subfractions (LDL1, LDL2, and LDL3) were prepared by density gradient ultracentrifugation at randomization and study end. Triglycerides, cholesterol, total protein, and phospholipids were measured and mass of subfractions calculated. HDL subfractions were prepared by precipitation. The primary end point was change in proportion of LDL as LDL3. RESULTS—HbA1c, triglycerides, glucose, and cholesterol were comparable across groups at baseline and over time. LDL3 mass and the LDL3-to-LDL ratio fell with pioglitazone (LDL3 mass 36.2 to 28.0 mg/dl, P < 0.01; LDL3-to-LDL 19.2:13.3%, P < 0.01) and metformin (42.7 to 31.5 mg/dl, P < 0.01; 21.3:16.2%, P < 0.01, respectively) with no change on gliclazide. LDL3 reductions were associated with reciprocal LDL1 increases. Changes were independent of BMI, glycemic control, and triglycerides. Total HDL cholesterol increased on pioglitazone (1.28 to 1.36 mmol/l, P = 0.02) but not gliclazide (1.39 to 1.37 mmol/l, P = NS) or metformin (1.26 to 1.18 mmol/l, P = NS), largely due to an HDL2 increase (0.3 to 0.4 mmol/l, P < 0.05). HDL3 cholesterol fell on metformin (0.9 to 0.85 mmol/l, P < 0.01). On pioglitazone and metformin, the HDL2-to-HDL3 ratio increased compared with no change on gliclazide. CONCLUSIONS—For the same improvement in glycemic control, pioglitazone and metformin produce favorable changes in HDL and LDL subfractions compared with gliclazide in overweight type 2 diabetic patients. Such changes may be associated with reduced atherosclerosis risk and may inform the choice of initial oral hypoglycemic agent.
- 1 January 2004
- Published by American Diabetes Association in Diabetes Care
- Vol. 27 (1) , 41-46
Favorable Effects of Pioglitazone and Metformin Compared With Gliclazide on Lipoprotein Subfractions in Overweight Patients With Early Type 2 Diabetes
OBJECTIVE—To compare effects of different oral hypoglycemic drugs as first-line therapy on lipoprotein subfractions in type 2 diabetes. RESEARCH DESIGN AND METHODS—Sixty overweight type 2 diabetic patients not on lipid-lowering therapy were randomized to metformin, pioglitazone, or gliclazide after a 3-month dietary run-in. Drug doses were uptitrated for 3 months to optimize glycemia and were kept fixed for a further 3 months. LDL subfractions (LDL1, LDL2, and LDL3) were prepared by density gradient ultracentrifugation at randomization and study end. Triglycerides, cholesterol, total protein, and phospholipids were measured and mass of subfractions calculated. HDL subfractions were prepared by precipitation. The primary end point was change in proportion of LDL as LDL3. RESULTS—HbA1c, triglycerides, glucose, and cholesterol were comparable across groups at baseline and over time. LDL3 mass and the LDL3-to-LDL ratio fell with pioglitazone (LDL3 mass 36.2 to 28.0 mg/dl, P < 0.01; LDL3-to-LDL 19.2:13.3%, P < 0.01) and metformin (42.7 to 31.5 mg/dl, P < 0.01; 21.3:16.2%, P < 0.01, respectively) with no change on gliclazide. LDL3 reductions were associated with reciprocal LDL1 increases. Changes were independent of BMI, glycemic control, and triglycerides. Total HDL cholesterol increased on pioglitazone (1.28 to 1.36 mmol/l, P = 0.02) but not gliclazide (1.39 to 1.37 mmol/l, P = NS) or metformin (1.26 to 1.18 mmol/l, P = NS), largely due to an HDL2 increase (0.3 to 0.4 mmol/l, P < 0.05). HDL3 cholesterol fell on metformin (0.9 to 0.85 mmol/l, P < 0.01). On pioglitazone and metformin, the HDL2-to-HDL3 ratio increased compared with no change on gliclazide. CONCLUSIONS—For the same improvement in glycemic control, pioglitazone and metformin produce favorable changes in HDL and LDL subfractions compared with gliclazide in overweight type 2 diabetic patients. Such changes may be associated with reduced atherosclerosis risk and may inform the choice of initial oral hypoglycemic agent.
- Open Access
- 1 April 2003
- Published by Wiley in Preventive Cardiology
- Vol. 6 (2) , 78-84
Screening for Diabetes in General Practice
The prevalence of type 2 diabetes is rising rapidly worldwide. Evidence suggests that between one third and one half of cases are undiagnosed and patients may have preclinical disease for as long as 12 years. At diagnosis, 50% of patients have microvascular complications (retinopathy, neuropathy, or nephropathy) and patients have twice the risk of macrovascular disease compared to the background population. Screening for type 2 diabetes would allow earlier recognition of cases, with the potential to intervene earlier in the disease course, but whether this would result in improved long‐term outcomes is unknown. The debate continues about who should be considered for screening, how we should screen, and whether we should screen for diabetes at all. The authors review the evidence, particularly in light of the recent position statement on diabetes screening published by the American Diabetes Association. If we do start screening for diabetes, one of the major challenges ahead is to ensure resources are in place to allow optimization of treatment for the increasing number of patients. This is important both in those found to have diabetes and in those with lesser degrees of glucose intolerance who are at high risk of developing diabetes and are at increased risk of macrovascular disease.
- 1 April 2003
- Published by Wiley in Preventive Cardiology
- Vol. 6 (2) , 78-84
Open AccessScreening for Diabetes in General Practice
The prevalence of type 2 diabetes is rising rapidly worldwide. Evidence suggests that between one third and one half of cases are undiagnosed and patients may have preclinical disease for as long as 12 years. At diagnosis, 50% of patients have microvascular complications (retinopathy, neuropathy, or nephropathy) and patients have twice the risk of macrovascular disease compared to the background population. Screening for type 2 diabetes would allow earlier recognition of cases, with the potential to intervene earlier in the disease course, but whether this would result in improved long‐term outcomes is unknown. The debate continues about who should be considered for screening, how we should screen, and whether we should screen for diabetes at all. The authors review the evidence, particularly in light of the recent position statement on diabetes screening published by the American Diabetes Association. If we do start screening for diabetes, one of the major challenges ahead is to ensure resources are in place to allow optimization of treatment for the increasing number of patients. This is important both in those found to have diabetes and in those with lesser degrees of glucose intolerance who are at high risk of developing diabetes and are at increased risk of macrovascular disease.
- 1 November 2002
- Published by Informa Healthcare in Expert Opinion on Pharmacotherapy
- Vol. 3 (11) , 1631-1641
Fluvastatin
Fluvastatin was the first wholly synthetic statin to the market and is effective in reducing total and low density lipoprotein cholesterol, which translates into reductions in coronary heart disease events. The Lescol Intervention Prevention Study has established the effectiveness of the early use of statins in reducing recurrent events in high-risk patients with coronary heart disease post percutaneous coronary interventions. Fluvastatin is well-tolerated with few side effects. The occurrence of significant abnormalities in liver enzymes is infrequent, and the risk of myositis and rhabdomyolysis seems to be less than with other statins. There have been no reports of fatal rhabdomyolysis to date. The potential for drug interactions with fluvastatin is low. It seems safe in combination with cyclosporin and there have been few reports of rhabdomyolysis when using fluvastatin in combination with other lipid-lowering agents. It is nevertheless important to be vigilant for this potentially important side effec...
- 1 November 2002
- Published by Informa Healthcare in Expert Opinion on Pharmacotherapy
- Vol. 3 (11) , 1631-1641
Fluvastatin
Fluvastatin was the first wholly synthetic statin to the market and is effective in reducing total and low density lipoprotein cholesterol, which translates into reductions in coronary heart disease events. The Lescol Intervention Prevention Study has established the effectiveness of the early use of statins in reducing recurrent events in high-risk patients with coronary heart disease post percutaneous coronary interventions. Fluvastatin is well-tolerated with few side effects. The occurrence of significant abnormalities in liver enzymes is infrequent, and the risk of myositis and rhabdomyolysis seems to be less than with other statins. There have been no reports of fatal rhabdomyolysis to date. The potential for drug interactions with fluvastatin is low. It seems safe in combination with cyclosporin and there have been few reports of rhabdomyolysis when using fluvastatin in combination with other lipid-lowering agents. It is nevertheless important to be vigilant for this potentially important side effec...
Screening for diabetes in general practice: cross sectional population study
Objective: To assess the policy proposed by the American Diabetes Association of universal screening in general practice of all patients aged over 45 years for diabetes. Design: Cross sectional population study. Setting: Local general practice in the United Kingdom. Participants: All patients aged over 45 not known to have diabetes. Main outcome measures: Prevalence of diabetes in the screened population, cardiovascular risk profile of patients diagnosed as having diabetes after screening. Results: Of 2481 patients aged over 45 and not known to have diabetes, 876 attended for screening. There were no significant demographic differences between the screened and unscreened patients. Prevalence of diabetes in patients with age as a sole risk factor was 0.2% (95% confidence interval 0% to 1.4%). Prevalence of diabetes in patients with age and one or more other risk factors (hypertension, obesity, or a family history of diabetes) was 2.8% (1.6% to 4.7%). Four hours a week for a year would be needed to screen all people over 45 in the practice's population; about half this time would be needed to screen patients with risk factors other than age. More than 80% of patients newly diagnosed as having diabetes had a 10 year risk of coronary heart disease >15%, 73% (45% to 92%) were hypertensive, and 73% (45% to 92%) had a cholesterol concentration >5 mmol/l. Conclusions: Screening for diabetes in general practice by measuring fasting blood glucose is feasible but has a very low yield in patients whose sole risk factor for diabetes is age over 45. Screening in a low risk population would best be targeted at patients with multiple risk factors. What is already known on this topic: Between a third and a half of cases of diabetes are undiagnosed at any one time New cases can be identified by screening groups of patients at risk The American Diabetes Association has proposed the screening of all patients aged over 45 every three years What this study adds: Screening for diabetes in general practice by measuring fasting blood glucose is feasible but requires much staff time Screening solely on the basis of age has a very low yield and screening would best be targeted at patients with multiple risk factors for diabetes
Screening for diabetes in general practice: cross sectional population study
Objective: To assess the policy proposed by the American Diabetes Association of universal screening in general practice of all patients aged over 45 years for diabetes. Design: Cross sectional population study. Setting: Local general practice in the United Kingdom. Participants: All patients aged over 45 not known to have diabetes. Main outcome measures: Prevalence of diabetes in the screened population, cardiovascular risk profile of patients diagnosed as having diabetes after screening. Results: Of 2481 patients aged over 45 and not known to have diabetes, 876 attended for screening. There were no significant demographic differences between the screened and unscreened patients. Prevalence of diabetes in patients with age as a sole risk factor was 0.2% (95% confidence interval 0% to 1.4%). Prevalence of diabetes in patients with age and one or more other risk factors (hypertension, obesity, or a family history of diabetes) was 2.8% (1.6% to 4.7%). Four hours a week for a year would be needed to screen all people over 45 in the practice's population; about half this time would be needed to screen patients with risk factors other than age. More than 80% of patients newly diagnosed as having diabetes had a 10 year risk of coronary heart disease >15%, 73% (45% to 92%) were hypertensive, and 73% (45% to 92%) had a cholesterol concentration >5 mmol/l. Conclusions: Screening for diabetes in general practice by measuring fasting blood glucose is feasible but has a very low yield in patients whose sole risk factor for diabetes is age over 45. Screening in a low risk population would best be targeted at patients with multiple risk factors. What is already known on this topic: Between a third and a half of cases of diabetes are undiagnosed at any one time New cases can be identified by screening groups of patients at risk The American Diabetes Association has proposed the screening of all patients aged over 45 every three years What this study adds: Screening for diabetes in general practice by measuring fasting blood glucose is feasible but requires much staff time Screening solely on the basis of age has a very low yield and screening would best be targeted at patients with multiple risk factors for diabetes